Antheia recently joined some of the industry’s most notable thought leaders at the prestigious Forbes Sustainability Leaders Summit, which gathered on September 20 in New York City to discuss insights, innovations, and visions for a more sustainable future. Antheia CEO and co-founder Dr. Christina Smolke had the honor of participating in a panel discussion that […]
Antheia’s Chief Operations Officer Zack McGahey offers his perspective on the company’s most recent commercial milestone – a successful full-scale fermentation run of its first product at 116,000L.
Brewer’s yeast engineered with synthetic biology to produce drugs or raw materials could transform pharmaceutical supply chains.
Antheia was founded in 2015 by Dr. Christina Smolke, CEO and Dr. Kristy Hawkins, CSO and is based in Menlo Park, California. Antheia’s co-founders are pioneers in the fields of synthetic biology and metabolic engineering and are applying these technologies to transform pharmaceutical supply chains in order to better support the needs of 21st century healthcare.
We continue to see the U.S. government setting policy priorities that underscore the importance of both building a robust American bioeconomy and strengthening domestic pharmaceutical supply chains – two core pillars of Antheia’s business and technology.
Synthetic chemistry is an essential part of drug development, opening the door for scientists to create complex small molecules with specific properties. Small molecule drugs – including household staples like aspirin and acetaminophen – currently make up the bulk of approved pharmaceuticals to date.
In a recent Q&A with European Pharmaceutical Manufacturer Antheia CEO and co-founder Dr. Christina Smolke discussed how latency and variability within agricultural supply chains remains the number one challenge in the pharmaceutical-grade production…
Antheia, a synthetic biology company enabling next-generation plant-inspired medicines, today announced $40 million in venture debt financing from Oxford Finance LLC and Silicon Valley Bank, alongside plans to construct a new pilot scale biomanufacturing facility.
Fundraising at Bota Bio, Genomatica, and Antheia signals an upshift for commercial-scale synthetic biology…
Company’s SynBio platform enables manufacturing of complex plant-based drugs Biomanufacturing and synthetic biology (SynBio) manufacturing platforms have the potential to create more resilient supply chains for essential medicines by producing…